BioCorRx (BICX) Research & Development (2017 - 2026)
BioCorRx (BICX) posted Research & Development of $352333.0 for Q1 2026, down 80.08% sequentially from $1.8 million in Q4 2025, and up 117.6% YoY from $161919.0 in Q1 2025.
Powered by 
Analysis
BioCorRx (BICX) Research & Development (2017 - 2026) Analysis & Trends
BioCorRx has reported Research & Development for 10 years, with the latest figure at $352333.0 in Q1 2026.
- Quarterly Research & Development rose 117.6% year-over-year to $352333.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 139.2% YoY) and the FY2025 annual result came in at $1.8 million, up 19.29% from the prior year.
- Research & Development retreated to $352333.0 in Q1 2026 per BICX's latest filing, from $1.8 million in the prior quarter.
- Over five years, Research & Development peaked at $1.8 million in Q4 2025 and troughed at $128295.0 in Q4 2023.
- A 5-year average of $436360.2 and a median of $296860.0 in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development slumped 76.07% in 2023, then jumped 549.06% in 2025.
- Over 5 years, Research & Development stood at $536104.0 in 2022, then plunged by 76.07% to $128295.0 in 2023, then surged by 112.43% to $272543.0 in 2024, then surged by 549.06% to $1.8 million in 2025, then plunged by 80.08% to $352333.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $352333.0, $1.8 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 90.36 Bn | 89.35 Bn | 15.19 Bn | - |
| 2 | Tenet Healthcare | 22.02 Bn | 19.85 Bn | 4.45 Bn | - |
| 3 | Encompass Health | 12.13 Bn | 11.99 Bn | 1.34 Bn | - |
| 4 | Davita | 11.78 Bn | 11.09 Bn | 1.16 Bn | - |
| 5 | Universal Health Services | 10.09 Bn | 9.95 Bn | 3.29 Bn | - |
| 6 | Ensign | 9.97 Bn | 9.65 Bn | 306.24 Mn | - |
| 7 | Chemed | 6.93 Bn | 6.89 Bn | 221.47 Mn | - |
| 8 | Pacs | 6.81 Bn | 6.64 Bn | 338.46 Mn | - |
| 9 | Concentra Group Holdings Parent | 4.32 Bn | 4.16 Bn | 192.10 Mn | - |
| 10 | BioCorRx | 3.46 Mn | 3.44 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 352,333.00 |
| Dec 31, 2025 | 305,515.00 |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 296,860.00 |
| Mar 31, 2025 | 161,919.00 |
| Dec 31, 2024 | 272,543.00 |
| Sep 30, 2024 | 460,138.00 |
| Jun 30, 2024 | 536,362.00 |
| Mar 31, 2024 | 213,834.00 |
| Dec 31, 2023 | 128,295.00 |
| Sep 30, 2023 | 286,962.00 |
| Jun 30, 2023 | 238,419.00 |
| Mar 31, 2023 | 237,387.00 |
| Dec 31, 2022 | 536,104.00 |
| Sep 30, 2022 | 342,553.00 |
| Jun 30, 2022 | 382,952.00 |
| Mar 31, 2022 | 197,849.00 |
| Dec 31, 2021 | 234,423.00 |
| Sep 30, 2021 | 589,985.00 |
| Jun 30, 2021 | 123,262.00 |